At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 310 enrolled
Drug / intervention
albiglutide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating albiglutide and placebo for Diabetes Mellitus, Type 2. Completed, enrolled 310 participants across 331 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesIndia, Peru, South Africa, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedFeb 2009
Primary CompletionNov 2011
Study CompletionJan 2013
TodayJul 2026
First PostedFeb 23, 2009
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2011
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.4 years ago
Interventions
albiglutidebiological
albiglutide weekly subcutaneous injection
placebodrug
placebo weekly subcutaneous injection